Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2011, Article ID 623673, 5 pages
http://dx.doi.org/10.1155/2011/623673
Review Article

An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost

1Department of Medicine, Division of Nephrology, Lankenau Medical Center, Suite 130 MOBW, 100 Lancaster Avenue, Wynnewood, PA 19096, USA
2Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA

Received 8 September 2010; Accepted 27 January 2011

Academic Editor: Maria Tsironi

Copyright © 2011 Geoffrey Teehan and Robert L. Benz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Nutritional Anaemias: Report of a WHO scientific group,” Tech. Rep. 405: 5–37, 1968. View at Google Scholar
  2. B. C. Astor, P. Muntner, A. Levin, J. A. Eustace, and J. Coresh, “Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey (1988–1994),” Archives of Internal Medicine, vol. 162, no. 12, pp. 1401–1408, 2002. View at Google Scholar · View at Scopus
  3. G. T. Obrador, T. Roberts, W. L. St. Peter W.L., E. Frazier, B. J. G. Pereira, and A. J. Collins, “Trends in anemia at initiation of dialysis in the United States,” Kidney International, vol. 60, no. 5, pp. 1875–1884, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. R. L. Benz, M. R. Pressman, E. T. Hovick, and D. D. Peterson, “A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study),” American Journal of Kidney Diseases, vol. 34, no. 6, pp. 1089–1095, 1999. View at Google Scholar · View at Scopus
  5. B. P. Teehan, S. Krantz, W. A. Stone et al., “Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients,” American Journal of Kidney Diseases, vol. 18, no. 1, pp. 50–59, 1991. View at Google Scholar
  6. D. A. Revicki, R. E. Brown, D. H. Feeny et al., “Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients,” American Journal of Kidney Diseases, vol. 25, no. 4, pp. 548–554, 1995. View at Google Scholar · View at Scopus
  7. C. G. Winearls, “Historical review on the use of recombinant human erythropoietin in chronic renal failure,” Nephrology Dialysis Transplantation, vol. 10, no. 2, pp. 3–9, 1995. View at Google Scholar · View at Scopus
  8. W. M. McClellan, W. D. Flanders, R. D. Langston, C. Jurkovitz, and R. Presley, “Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1928–1936, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Phrommintikul, S. J. Haas, M. Elsik, and H. Krum, “Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis,” Lancet, vol. 369, no. 9559, pp. 381–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. B. J. Barrett, S. S. Fenton, B. Ferguson et al., “Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology,” Journal of the American Society of Nephrology, vol. 10, pp. S292–S296, 1999. View at Google Scholar · View at Scopus
  12. J. S. Cameron, “European best practice guidelines for the management of anaemia in patients with chronic renal failure,” Nephrology Dialysis Transplantation, vol. 14, no. 2, pp. 61–65, 1999. View at Google Scholar · View at Scopus
  13. F. Gejyo, A. Saito, T. Akizawa et al., “2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients,” Therapeutic Apheresis and Dialysis, vol. 8, no. 6, pp. 443–459, 2004. View at Google Scholar · View at Scopus
  14. Y. Hirasawa, N. Itami, T. Mizuno et al., “Maintenance hamatocrit levels and mortality in hemodialysis patients with renal anemia receiving recombinant human erythropoietin(rHuEPO) treatment(rHuEPO survey),” Journal of Japanese Society for Dialysis Therapy, vol. 36, no. 7, pp. 1265–1272, 2003. View at Google Scholar
  15. F. Locatelli, A. R. Nissenson, B. J. Barrett et al., “Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease. Improving Global Outcomes (KDIGO),” Kidney International, vol. 74, no. 10, pp. 1237–1240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. National Kidney Foundation-KDOQI, “Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease,” American Journal of Kidney Diseases, vol. 50, p. 474, 2007. View at Google Scholar
  17. J. Bohlius, K. Schmidlin, C. Brillant et al., “Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials,” The Lancet, vol. 373, no. 9674, pp. 1532–1542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. FDA, “FDA black box warning for Aranesp. Silver Spring, MD: food and drug administration,” 2009, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103951s5195PI.pdf.
  19. B. Leyland-Jones, V. Semiglazov, M. Pawlicki et al., “Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5960–5972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Painter, “The importance of exercise training in rehabilitation of patients with end-stage renal disease,” American Journal of Kidney Diseases, vol. 24, no. 1, supplement 1, pp. S2–S9, 1994, discussion pp. S31-S32. View at Google Scholar
  21. M. Moia, L. Vizzotto, M. Cattaneo, P. M. Mannucci, S. Casati, and C. Ponticelli, “Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin,” Lancet, vol. 2, no. 8570, pp. 1227–1229, 1987. View at Google Scholar · View at Scopus
  22. T. B. Drüeke, F. Locatelli, N. Clyne et al., “Normalization of hemoglobin level in patients with chronic kidney disease and anemia,” New England Journal of Medicine, vol. 355, no. 20, pp. 2071–2084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Pfeffer, E. A. Burdmann, C. Y. Chen et al., “A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease,” New England Journal of Medicine, vol. 361, no. 21, pp. 2019–2032, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. U. Eckardt, A. Scherhag, I. C. Macdougall et al., “Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2651–2660, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. D. E. Weiner, H. Tighiouart, P. T. Vlagopoulos et al., “Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1803–1810, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Besarab, W. K. Bolton, J. K. Browne et al., “The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin,” New England Journal of Medicine, vol. 339, no. 9, pp. 584–590, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Levin, “Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge,” Kidney International, Supplement, vol. 61, no. 80, pp. S35–S38, 2002. View at Google Scholar · View at Scopus
  28. A. Oral, “the complete correction of post-transplant anemia reduces the rate of progression of chronic allograft nephropathy,” American Journal of Transplantation, vol. 10, p. 141, 2010. View at Google Scholar